1024 Faecal Calprotectin Measured by IBD Patients at Home - A New Clinical Tool

Abstract

significantly younger, had shorter disease duration and underwent a greater number of CD related surgeries during the study period (Table 1). For the entire study cohort, LS1 ranged from 0-54 (mean 8.76±6), LS2 ranged from 0-46 (mean 9.98±8) and DLS ranged from -17 to 32 (mean 1.17±0). Based on DLS, five trajectories were created (A: DLS 5.36). Patients with silent CD had a significantly higher DLS compared to asymptomatic CD patients with no objective evidence of inflammation. A greater proportion of silent CD patients fell under trajectory D and E that signified progression of damage (Figure 1). CONCLUSION: CD patients, with silent disease (good quality of life but elevated CRP), demonstrate a higher likelihood of progression of bowel damage over 5y compared to asymptomatic CD patients with no objective evidence of inflammation. This may be attributed to the underestimation and more conservative treatment approach of this entity. Patients with silent CD may benefit from further evaluation, closer monitoring and possible aggressive management. Table 1: Baseline characteristics and Lemann scores for the study population